Trial Profile
A Phase II study of Pemetrexed/Bevacizumab in patients ineligible for platinum-based chemotherapy with untreated Advanced Non-squamous non-small-cell lung cancer (ALCT003)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jun 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 27 May 2013 New trial record